Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/125906
Title: | Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions |
Author: | Caniglia, Ellen C. Cain, Lauren E. Justice, Amy C. Tate, Janet Logan, Roger Sabin, Caroline Winston, Alan Sighem, Ard van Miró Meda, José M. Podzamczer Palter, Daniel Olson, Ashley D. Arribas, José Ramón Moreno Guillén, Santiago Meyer, Laurence Romero, Jorge del Dabis, François Bucher, Heiner C. Wandeler, Gilles Vourli, Georgia Skoutelis, Athanasios Lanoy, Emilie Gasnault, Jacques Costagliola, Dominique Hernán, Miguel A. HIV-CAUSAL Collaboration |
Keywords: | Sida Antiretrovirals Manifestacions neurològiques de les malalties AIDS (Disease) Antiretroviral agents Neurologic manifestations of general diseases |
Issue Date: | 6-Jun-2014 |
Publisher: | Lippincott, Williams & Wilkins. Wolters Kluwer Health |
Abstract: | Objective: The link between CNS penetration of antiretrovirals and AIDS-defining neurologic disorders remains largely unknown. Methods: HIV-infected, antiretroviral therapy-naive individuals in the HIV-CAUSAL Collaboration who started an antiretroviral regimen were classified according to the CNS Penetration Effectiveness (CPE) score of their initial regimen into low (,8), medium (8-9), or high (.9) CPE score. We estimated "intention-to-treat" hazard ratios of 4 neuroAIDS conditions for baseline regimens with high and medium CPE scores compared with regimens with a low score. We used inverse probability weighting to adjust for potential bias due to infrequent follow-up. Results: A total of 61,938 individuals were followed for a median (interquartile range) of 37 (18, 70) months. During follow-up, there were 235 cases of HIV dementia, 169 cases of toxoplasmosis, 128 cases of cryptococcal meningitis, and 141 cases of progressive multifocal leukoencephalopathy. The hazard ratio (95% confidence interval) for initiating a combined antiretroviral therapy regimen with a high vs low CPE score was 1.74 (1.15, 2.65) for HIV dementia, 0.90 (0.50, 1.62) for toxoplasmosis, 1.13 (0.61, 2.11) for cryptococcal meningitis, and 1.32 (0.71, 2.47) for progressive multifocal leukoencephalopathy. The respective hazard ratios (95% confidence intervals) for a medium vs low CPE score were 1.01 (0.73, 1.39), 0.80 (0.56, 1.15), 1.08 (0.73, 1.62), and 1.08 (0.73, 1.58). Conclusions: We estimated that initiation of a combined antiretroviral therapy regimen with a high CPE score increases the risk of HIV dementia, but not of other neuroAIDS conditions. |
Note: | Reproducció del document publicat a: https://doi.org/10.1212/WNL.0000000000000564 |
It is part of: | Neurology, 2014, vol. 83, num. 2, p. 134-141 |
URI: | https://hdl.handle.net/2445/125906 |
Related resource: | https://doi.org/10.1212/WNL.0000000000000564 |
ISSN: | 0028-3878 |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
649374.pdf | 446.21 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.